$DOCS

Sitaram Siddharth sold $44K of DOCS

Sitaram Siddharth (Chief Accounting Officer) sold 1,770 shares of Doximity, Inc. (DOCS) at $24.94 on 2026-08-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sitaram Siddharth
Published Aug 17, 2026, 10:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 11:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DOCS
Neutral
high confidence
Mentioned
$DOCS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DOCSNeutralLow
01

Why it matters

This is a disclosed open-market sale by a named officer, executed under a pre-arranged Rule 10b5-1 plan, with no other corporate event described.

02

Market read

Traders may log the transaction for sentiment monitoring, but it is unlikely to drive a fundamental repricing without additional news.

03

What to watch

The article provides only the sale details; it does not include any offsetting buys, changes in compensation, or new company-specific catalysts.

Relevance 2/10Novelty 2/10Timing: Filed after-hours on 2026-08-17, reflecting a sale executed 2026-08-13.

Background

The article is an SEC Form 4 insider transaction disclosure for Doximity, Inc. (DOCS).

Company-level read

Ticker impact

$DOCSNeutralHigh confidence
Context

Doximity insider Form 4 shows Chief Accounting Officer Sitaram Siddharth sold 1,770 shares for about $44.1K under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a disclosed open-market sale by an officer, explicitly under a pre-arranged 10b5-1 plan, with no accompanying guidance, deal, or regulatory event.

Market effects

No clear sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with personal liquidity needs or risk management, which some traders may still monitor.

Key entities

  • Doximity, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Sitaram Siddharth

    Chief Accounting Officer who sold 1,770 shares.

  • Rule 10b5-1 plan

    Pre-arranged plan indicating the sale was scheduled in advance.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

MedAI 8/10

Doximity’s ex-chief revenue officer to pay nearly $500K to SEC: Trial Balance

Doximity's former chief revenue officer, Paul Jorgensen, was ordered to pay $490,000 to the SEC for insider trading. He sold shares based on nonpublic information ahead of negative earnings announcements, avoiding losses and making $2.2 million in profits. Jorgensen was also sentenced to 26 months in prison and ordered to forfeit $2.5 million in a parallel criminal case.

$DOCSMed

Doximity stock falls as Freedom Capital cuts to hold

Doximity Inc (DOCS) shares dropped 5.6% after Freedom Capital downgraded it to Hold, raising its price target to $27. The company beat Q1 estimates, increased full-year revenue guidance, but lowered EBITDA outlook due to AI investment. Freedom Capital noted strong AI search traction but margin concerns and core business softening.

$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 2027 revenue of $156.6 million, up 7% year over year, and adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million. It said AI workflow and scribe usage grew, repurchased $91.6 million of stock, and ended June 30 with $688 million in cash and marketable securities.

$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 FY2027 revenue of $156.6 million, up 7% year over year, with adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million and adjusted EBITDA guidance to $309 million to $329 million. It also repurchased $91.6 million of stock and ended June 30 with $688 million cash and marketable securities.